Oxidation by hypochlorite converts protective HDL into a potent platelet agonist

FEBS Letters

Volumn 582, Issue 5, 2008, Pages 778-784

  Assinger, Alice ^a   Schmid, Werner ^a   Eder, Sandra ^a   Schmid, Diethart ^a   Koller, Elisabeth ^a   Volf, Ivo ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; High density lipoprotein; Hypochlorite; Oxidative stress; Platelet aggregation; Thrombosis

Indexed keywords

CD36 ANTIGEN; HIGH DENSITY LIPOPROTEIN; HYPOCHLORITE; PADGEM PROTEIN; THROMBOSPONDIN;

ARTICLE; CELL FUNCTION; CONTROLLED STUDY; HUMAN; OXIDATION; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; BLOOD PLATELETS; CALCIUM; HUMANS; HYPOCHLOROUS ACID; INTRACELLULAR SPACE; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; P-SELECTIN; PLATELET AGGREGATION;

EID: 39649085345     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.02.001     Document Type: Article

References (28)

1. Ross R. Atherosclerosis-an inflammatory disease. New Engl. J. Med. 340 (1999) 115-126
2. Relou I.A.M., Hackeng C.M., Akkerman J.W.N., and Malle E. Low-density lipoprotein and its effect on human blood platelets. Cell. Mol. Life Sci. 60 (2003) 961-971
3. Koller E., Volf I., Gurvitz A., and Koller F. Modified low-density lipoproteins and high-density lipoproteins. From investigation tools to real in vivo players. Pathophysiol. Haemost. Thromb. 35 (2006) 322-345
4. Nofer J.R., Kehrel B., Fobker M., Levkau B., Assmann G., and von Eckardstein A. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis 161 (2002) 1-16
5. von Eckardstein A., Nofer J.R., and Assmann G. High density lipoproteins and arteriosclerosis - role of cholesterol efflux and reverse cholesterol transport. Arterioscl. Throm. Vas. Biol. 21 (2001) 13-27
6. Mineo C., and Shaul P.W. Modulation of endothelial NO production by high-density lipoprotein. Cold Spring Harb Symp Quant. Biol. 67 (2002) 459-469
7. Ansell B.J., Fonarow G.C., and Fogelman A.M. The paradox of dysfunctional high-density lipoprotein. Curr. Opin. Lipidol. 18 (2007) 427-434
8. Nakano T., and Nagata A. Immunochemical detection of circulating oxidized high-density lipoprotein with antioxidized apolipoprotein A-I monoclonal antibody. J. Lab. Clin. Med. 141 (2003) 378-384
9. Nakajima T., Origuchi N., Matsunaga T., Kawai S., Hokari S., Nakamura H., Inoue I., Katayama S., Nagata A., and Komoda T. Localization of oxidized HDL in atheromatous plaques and oxidized HDL binding sites on human aortic endothelial cells. Ann. Clin. Biochem. 37 (2000) 179-186
10. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
11. Volf I., Roth A., Cooper J., Moeslinger T., and Koller E. Hypochlorite modified LDL are a stronger agonist for platelets than copper oxidized LDL. FEBS Lett. 483 (2000) 155-159
12. Noble R.P. Electrophoretic separation of plasma lipoproteins in agarose gel. J. Lipid Res. 9 (1968) 693-700
13. Bohlen P., Stein S., Dairman W., and Udenfriend S. Fluorometric assay of proteins in the nanogram range. Arch. Biochem. Biophys. 155 (1973) 213-220
14. Vissers M.C.M., and Winterbourn C.C. Oxidative damage to fibronectin. 1. The effects of the neutrophil myeloperoxidase system and HOCl. Arch. Biochem. Biophys. 285 (1991) 53-59
15. Battye F.L. Web servlet-assisted, dial-in flow cytometry data analysis. Cytometry 43 (2001) 143-149
16. Chen L.Y., and Mehta J.L. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci. 55 (1994) 1815-1821
17. Nofer J.R., Walter M., Kehrel B., Wierwille S., Tepel M., Seedorf U., and Assmann G. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscl. Thromb. Vas. Biol. 18 (1998) 861-869
18. Barter P.J., Nicholls S., Rye K.A., Anantharamaiah G.M., Navab M., and Fogelman A.M. Antiinflammatory properties of HDL. Circ. Res. 95 (2004) 764-772
19. Malle E., Marsche G., Panzenboeck U., and Sattler W. Myeloperoxidase-mediated oxidation of high-density lipoproteins: fingerprints of newly recognized potential proatherogenic lipoproteins. Arch. Biochem. Biophys. 445 (2006) 245-255
20. Zhang Z.L., Brennan M.L., Fu X.M., Aviles R.J., Pearce G.L., Penn M.S., Topol E.J., Sprecher D.L., and Hazen S.L. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA - J. Am. Med. Assoc. 286 (2001) 2136-2142
21. Kutter D., Devaquet P., Vanderstocken G., Paulus J.M., Marchal V., and Gothot A. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol. 104 (2000) 10-15
22. Panzenboeck U., Raitmayer S., Reicher H., Lindner H., Glatter O., Malle E., and Sattler W. Effects of reagent and enzymatically generated hypochlorite on physicochemical and metabolic properties of high density lipoproteins. J. Biol. Chem. 272 (1997) 29711-29720
23. Calvo D., Gomez Coronado D., Suarez Y., Lasuncion M.A., and Vega M.A. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J. Lipid Res. 39 (1998) 777-788
24. Thorne R.F., Mhaidat N.M., Ralston K.J., and Burns G.F. CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett. 581 (2007) 1227-1232
25. Ankersmit H.J., Roth G.A., Moser B., Zuckermann A., Brunner M., Rosin C., Buchta C., Bielek E., Schmid W., Jensen-Jarolim E., Wolner E., Boltz-Nitulescu G., and Volf I. CD32-mediated platelet aggregation in vitro by anti-thymocyte globulin: implication of therapy-induced in vivo thrombocytopenia. Am. J. Transplant. 3 (2003) 754-759
26. Opper C., Schüssler G., Sattler W., and Malle E. Effect of hypochlorite (HOCl)-modified low density lipoproteins and high density lipoproteins on platelet function. Platelets 9 (1998) 339-341
27. (2+)-ATPase activity of human platelets. Cell Calcium 26 (1999) 281-287
28. -), a product of the myeloperoxidase system, degrades articular cartilage proteoglycan aggregate. Free Radic. Biol. Med. 10 (1991) 101-109